Champions Oncology, Inc. (Nasdaq:CSBR), a translational oncology research organization, announced its financial results for the fiscal year and fourth quarter ending April 30, 2025. The company reported record annual revenue of $57 million, marking a 14% increase year-over-year. Net income for the fiscal year was $4.6 million, and adjusted EBITDA income reached $7.1 million. Total oncology revenue for fiscal year 2025 was $56.9 million, up from $50.2 million in the previous year, attributed to a 4% growth in research services and $4.7 million from data license revenue. Operating expenses decreased by 9% to $52.4 million for fiscal year 2025. For the fourth quarter, total revenue was $12.3 million, with a reported adjusted EBITDA loss of $1.2 million. Total oncology revenue for the fourth quarter was $12.4 million, representing a 12% decrease from the previous year's $14.0 million, but aligning with expectations. Operating cash flow for the quarter was $6.4 million, and new data licensing revenue contributed approximately $200,000. David Miller, CFO of Champions, highlighted the company's fiscal 2025 financial turnaround, driven by disciplined execution and operational efficiency, leading to record adjusted EBITDA and a strengthened balance sheet. The company expresses confidence in building upon this momentum in fiscal 2026. Full financial details will be available in the Company's Form 10-K by July 29, 2025.